TrialNature communications2025

A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19.

Jung Ho Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.